What You Should Know
- The FDA’s October 2026 approval of pirtobrutinib gives adults with previously untreated CLL/SLL without a known 17p deletion another chemotherapy‑free option, adding flexibility rather than replacing existing frontline therapies. It’s a daily pill taken continuously until the disease progresses or side effects require stopping, unlike some CLL treatments given for a fixed period.
- Experts emphasize personalization: Dr. Marc Hoffman notes the approval “does not dramatically change treatment for the majority of patients” but offers an option for select patients with specific cardiovascular problems, while Dr. Omar Alkharabsheh says it helps doctors tailor treatment to a patient’s other health conditions, preferences, and goals.
- With multiple highly effective therapies now available, sequencing is increasingly important; Dr. Victor Yazbeck describes the current landscape as an “embarrassment of riches,” underscoring the challenge of choosing “which treatment is best for which patient and in what sequence.”
The approval gives doctors another chemotherapy-free treatment option for people who require treatment.
Read MoreA Newer BTK Inhibitor
Pirtobrutinib is a newer BTK inhibitor, a targeted therapy that blocks a protein called BTK, which helps CLL cells grow and survive. Unlike earlier BTK inhibitors, pirtobrutinib attaches to BTK in a different, reversible way. It has also shown activity in people whose CLL has previously been treated with another type of BTK inhibitor and stopped responding.This approval was supported by results from the BRUIN CLL-313 trial, which included 282 people with previously untreated CLL/SLL without a known 17p deletion. Patients receiving pirtobrutinib had a significantly longer period before their disease progressed or they died compared with those receiving bendamustine plus rituximab.
After about 28 months of follow-up, most people taking pirtobrutinib had not experienced their CLL getting worse, so the typical time before progression had not yet been reached. In the comparison group, that median was about 33.5 months.
Expert Resources for CLL Patients
- CLL is Not Considered Curable So Treatment May Resume Years Later
- CLL Patients: Staying Ahead of Infections and Other Potential Cancers
- ‘Game Changing’ New Treatment Gives Hope to Relapsed CLL Patients
- ‘The Eye of the Tiger’ — Why Mindset and Lifestyle are So Important During Treatment for CLL
- Jaypirca: A New Beacon of Hope in the Fight Against Chronic Lymphocytic Leukemia
- How BTK Inhibitors Like Pirtobrutinib (Jaypirca) Fit Into Chronic Lymphocytic Leukemia Treatment Today
Pirtobrutinib offers another effective oral treatment. In the BRUIN CLL-313 trial, patients took pirtobrutinib daily until their disease progressed or side effects required stopping treatment. This differs from some CLL therapies designed to be given for a defined period and then stopped.
Dr. Marc Hoffman, Director of the Lymphoma Program at The University of Kansas Cancer Center, emphasized that the approval will likely be most meaningful for selected patients rather than representing a wholesale change for everyone with CLL.
“The recent approval of pirtobrutinib in the frontline setting does not dramatically change treatment for the majority of patients but does offer an additional option to a select group of patients who may have very specific cardiovascular problems in addition to their CLL.”
This matters because CLL treatment is increasingly individualized. A person’s age, other medical conditions, medications, potential side effects, and preferences about continuous versus time-limited treatment can all influence the choice.
The approval “expands the ability to personalize treatment decisions based on a patient’s comorbidities, preferences, and treatment goals,” said Dr. Omar Alkharabsheh, a medical oncologist with Orlando Health Cancer Institute in Florida.
For patients, this means conversations with their hematologist may increasingly focus not only on which treatment works, but on which treatment best fits their individual circumstances and which options they may want to preserve for the future.
With multiple highly effective treatments now available, the challenge is determining “which treatment is best for which patient and in what sequence,” said Dr. Victor Yazbeck, Director of Lymphoid Malignancies at VCU Massey Comprehensive Cancer Center in Richmond, Virginia. He called the current landscape an “embarrassment of riches.”
RELATED: Managing Quality of Life and Treatment Side Effects for CLL Patients
That sequencing question is becoming increasingly important because pirtobrutinib has demonstrated activity in patients previously treated with other BTK inhibitors, and researchers are also studying it in combination with other targeted therapies.
Dr. Hoffman, for example, is particularly interested in the potential role of pirtobrutinib combined with venetoclax and rituximab for patients whose CLL has returned after prior treatment, noting that “outcomes for this are incredibly favorable and practice-changing for patients with relapsed CLL.”
What This Means for You
Ultimately, the new approval represents another step forward for people with CLL/SLL. It does not mean that pirtobrutinib is the right treatment for everyone, but it gives physicians another effective chemotherapy-free option and greater flexibility to tailor treatment.
For patients, the key takeaway is that treatment decisions can increasingly be personalized around disease biology, overall health, potential side effects, treatment preferences, and future treatment options.
Learn more about SurvivorNet's rigorous medical review process.
